Oncology Meeting Digest

Breast

4 studies across 1 date

2026-05-17

EORTC 22922/10925 — 20-year results

Twenty-year EORTC 22922 data extend OS and DFS benefit from IM-MSC irradiation, with a new pN0 subgroup analysis.

  • No effect size in source tweet; images not accessible for extraction.
  • Prior 10-year data (Poortmans et al., NEJM 2015) showed borderline OS benefit and significant BCSS/DFS improvement; 20-year maturity likely resolves the OS signal.
  • Extension to pN0 subgroup is the clinically significant new analysis — IM-MSC RT benefit in node-negative, medially located tumors was previously undefined.
  • Era of enrollment (1996-2004) predates aromatase inhibitors and CDK4/6 inhibitors; absolute RT benefit may be attenuated in contemporary luminal patients on extended ET.
  • Open-label randomised design; competing mortality and intervening systemic therapy changes complicate direct causal attribution at 20 years.
📚 Sources (1)

IMPORT HIGH — 10-year results

Ten-year IMPORT HIGH results mature the dose-escalated simultaneous integrated boost signal in early breast cancer; tweet text truncated.

  • No effect size in tweet text; tweet is cut off mid-sentence.
  • Images (tweet 9, images 1-4) not accessible.
  • Trial (ISRCTN47437448) previously showed that higher SIB doses (48 Gy, 53 Gy vs 40 Gy control, all in 15#) reduced local recurrence without significantly increasing late effects at 5 years.
  • Ten-year maturity is the critical endpoint for late fibrosis, which was dose-dependent in 5-year data — highest SIB arm (53 Gy) had a signal worth following.
  • UK framing: IMPORT HIGH SIB data must now be interpreted alongside FAST-Forward (5#) — informs whether dose escalation adds value within abbreviated fractionation.
📚 Sources (1)

APBI-IMRT Florence Phase III — 15-year results

Fifteen-year APBI-IMRT Florence data assess durability of APBI non-inferiority vs whole-breast irradiation in selected early breast cancer.

  • No effect size in tweet text; images not accessible.
  • Trial previously demonstrated APBI non-inferiority for 5-year local relapse-free survival in node-negative, ER+ early breast cancer using IMRT-based external beam.
  • Fifteen years is the critical horizon for late hormone receptor-positive relapse — any LR curve divergence at this point would undermine the non-inferiority conclusion.
  • IMRT-based APBI (external beam) is methodologically distinct from GEC-ESTRO brachytherapy-based APBI; non-inferiority boundaries are not directly transferable.
  • Tweet 8 commentary ('suboptimal adherence to ET' affecting local control) is a relevant confound: luminal disease with non-adherent ET inflates LR risk independent of RT volume, potentially biasing APBI vs WBI comparison.
  • If non-inferiority is preserved at 15 years, this constitutes the longest APBI validation in a prospective randomised trial — clinically practice-changing for patient selection.
📚 Sources (2)

OLIGOMA trial — metastases-directed treatment in oligometastatic breast cancer NCT04495309

OLIGOMA (ARO-2021-09, NCT04495309) reports MDT outcomes in oligometastatic breast cancer; no effect size in source tweet.

  • No effect size or primary endpoint result in source tweet; images not accessible.
  • German ARO-sponsored prospective trial; design (randomised vs registry) not specified in tweet text.
  • Breast-specific oligometastatic MDT data are limited: NRG-BR002 (phase II, n=125) showed non-significant PFS improvement with SBRT vs standard care — OLIGOMA adds a disease-specific prospective dataset.
  • Receptor subtype breakdown is critical: ER+ de novo oligometastatic disease (systemic options include CDK4/6i) differs fundamentally from TNBC in expected RT benefit magnitude.
  • Without randomised design confirmation, selection bias toward favorable oligometastatic phenotype remains the principal methodological concern.
📚 Sources (1)